January 1, 2001American Journal of Medical Genetics
Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: A population study
Why the study?
Does the SUR1 intron 16-3t-->c polymorphism increase the risk of NIDDM and modulate the efficiency of sulfonylurea therapy?
Population
1,372 French men and women aged 35-64 years, including 122 subjects with non-insulin-dependent diabetes…
Comparison
Presence of the SUR1 intron 16-3t-->c… vs Absence of the polymorphism.
Design
Case-control
Authors
Discussion
Loading...
Member takes
Overview
May refine NIDDM risk stratification; leaves open pharmacogenetic effects on sulfonylurea response.
Structured PICO
Does the SUR1 intron 16-3t-->c polymorphism increase the risk of NIDDM and modulate the efficiency of sulfonylurea therapy?
P
Population
1,372 French men and women aged 35-64 years, including 122 subjects with non-insulin-dependent diabetes mellitus (NIDDM) and 1,250 controls.
I
Intervention
Presence of the SUR1 intron 16-3t-->c polymorphism (cc genotype or bearing at least one -3c allele).
C
Comparator
Absence of the polymorphism (tt homozygous genotype).
O
Outcome
Prevalence of non-insulin-dependent diabetes mellitus (NIDDM).
The SUR1 intron 16-3t-->c polymorphism is associated with increased susceptibility to type 2 diabetes and may enhance the triglyceride-lowering effect of sulfonylurea therapy.
Cite This Study
Meirhaeghe et al. (2001) studied this question.